×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AVXL – anavex life sciences corp. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AVXL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/24
10:30 am
avxl
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
Low
Report
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
12/22
08:02 am
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
12/18
07:30 am
avxl
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
Low
Report
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
12/17
10:20 am
avxl
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
Low
Report
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
12/15
08:06 am
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Medium
Report
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
12/12
05:32 pm
avxl
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease [Yahoo! Finance]
Medium
Report
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease [Yahoo! Finance]
12/12
04:05 pm
avxl
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
Low
Report
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
12/11
10:00 am
avxl
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Neutral
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Date
Time
Symbol
Company Name
Action
%Chg
11/25/2025
07:30 am
avxl
anavex life sciences corp.
BEAT
Report
9.8%
anavex life sciences corp.
8/12/2025
07:30 am
avxl
anavex life sciences corp.
MISS
Report
-0.7%
anavex life sciences corp.
5/13/2025
07:30 am
avxl
anavex life sciences corp.
BEAT
Report
-5.7%
anavex life sciences corp.
2/12/2025
07:30 am
avxl
anavex life sciences corp.
BEAT
Report
3.8%
anavex life sciences corp.
Date
Time
Symbol
Headline
Impact
11/25
04:32 pm
avxl
Form 10-K ANAVEX LIFE SCIENCES For: Sep 30
High
Report
Form 10-K ANAVEX LIFE SCIENCES For: Sep 30
11/25
07:31 am
avxl
Form 8-K ANAVEX LIFE SCIENCES For: Nov 25
High
Report
Form 8-K ANAVEX LIFE SCIENCES For: Nov 25
10/3
08:43 pm
avxl
Form 4 ANAVEX LIFE SCIENCES For: Oct 02 Filed by: Boenisch Sandra
Low
Report
Form 4 ANAVEX LIFE SCIENCES For: Oct 02 Filed by: Boenisch Sandra
10/3
08:42 pm
avxl
Form 4 ANAVEX LIFE SCIENCES For: Oct 02 Filed by: MISSLING CHRISTOPHER U
Low
Report
Form 4 ANAVEX LIFE SCIENCES For: Oct 02 Filed by: MISSLING CHRISTOPHER U
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/4
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Conference
30.6%
9/13 Form S-3/A ANAVEX LIFE SCIENCES 18.1%
3/23 Form DEFA14A ANAVEX LIFE SCIENCES 12.4%
2/14 Form SC 13G/A ANAVEX LIFE SCIENCES Filed by: Park West Asset Management LLC 11.9%
2/6 Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates 9.2%
2/4 Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference 8.8%
2/3 Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett Syndrome 5.1%
4/8 Form 8-K ANAVEX LIFE SCIENCES For: Apr 07 5.1%
12/5 Omeros, Anavex Results Positive, Protagonist Suffers Setback: The Good, Bad, And Ugly Of Biopharma [Seeking Alpha] 4.9%
6/18 Anavex Life Sciences Corp (NASDAQ: AVXL) is now covered by analysts at Janney Montgomery Scott. They set a "buy" rating on the stock. 4.5%
9/13 Form S-3/A ANAVEX LIFE SCIENCES 18.1%
3/23 Form DEFA14A ANAVEX LIFE SCIENCES 12.4%
2/14 Form SC 13G/A ANAVEX LIFE SCIENCES Filed by: Park West Asset Management LLC 11.9%
2/6 Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates 9.2%
2/4 Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference 8.8%
2/3 Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett Syndrome 5.1%
4/8 Form 8-K ANAVEX LIFE SCIENCES For: Apr 07 5.1%
12/5 Omeros, Anavex Results Positive, Protagonist Suffers Setback: The Good, Bad, And Ugly Of Biopharma [Seeking Alpha] 4.9%
6/18 Anavex Life Sciences Corp (NASDAQ: AVXL) is now covered by analysts at Janney Montgomery Scott. They set a "buy" rating on the stock. 4.5%
TOP News Decliners
4/1
Anavex Life Sciences Corp (NASDAQ: AVXL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
-10.5%
9/27 Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study -9.7%
7/3 Form S-3 ANAVEX LIFE SCIENCES -8.9%
7/29 Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome -8.7%
2/26 Anavex Life Sciences Corp (NASDAQ: AVXL) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. -8.0%
6/13 Anavex Life Sciences Corp (NASDAQ: AVXL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.3%
2/24 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS) -7.3%
2/6 Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q1 2020 Results - Earnings Call Transcript [Seeking Alpha] -7.2%
11/6 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome -5.9%
3/31 Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19 -4.8%
9/27 Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study -9.7%
7/3 Form S-3 ANAVEX LIFE SCIENCES -8.9%
7/29 Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome -8.7%
2/26 Anavex Life Sciences Corp (NASDAQ: AVXL) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. -8.0%
6/13 Anavex Life Sciences Corp (NASDAQ: AVXL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.3%
2/24 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS) -7.3%
2/6 Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q1 2020 Results - Earnings Call Transcript [Seeking Alpha] -7.2%
11/6 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome -5.9%
3/31 Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19 -4.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: